DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a report released on Tuesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a report on Thursday, November 14th.

DURECT Trading Up 2.3 %

DRRX stock opened at $0.82 on Tuesday. The business has a 50 day simple moving average of $0.80 and a 200-day simple moving average of $1.06. DURECT has a twelve month low of $0.70 and a twelve month high of $1.88. The company has a market capitalization of $25.40 million, a P/E ratio of -1.34 and a beta of 0.91.

Institutional Investors Weigh In On DURECT

Several hedge funds have recently modified their holdings of DRRX. Geode Capital Management LLC lifted its holdings in DURECT by 4.8% in the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 14,658 shares during the period. Jane Street Group LLC lifted its holdings in DURECT by 266.0% in the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 28,486 shares during the period. Finally, Richmond Brothers Inc. lifted its holdings in DURECT by 12.2% in the fourth quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after acquiring an additional 138,920 shares during the period. 28.03% of the stock is owned by institutional investors and hedge funds.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.